Ironwood's bowel disease treatment meets main goal in late-stage trial

Ironwood Pharmaceuticals (IRWD.O) said on Thursday that its treatment for a condition associated with chronic intestinal failure met the main goal of reducing dependency on supported nutrition in a late-stage trial.